Helicobacter Pylori Eradication and Irritable Bowel Syndrome: A Prospective Study

Assiut University

Status and phase: Unknown; Phase 4

Conditions: Irritable Bowel Syndrome

Treatments: Drug: Triple therapy for H.pylori

Study type: Interventional

Funder types: Other

Identifiers

NCT04512898

H. Pylori

Details and patient eligibility

About

H. Pylori is frequently observed in patients with irritable bowel syndrome(IBS). However, the effect of H. pylori eradication on IBS is not clear.

Full description

Patients with IBS symptoms using Rome IV criteria will be included. Testing for H. pylori will be done. Patients with H. pylori will receive triple therapy and followed after two weeks for eradication and assessment of IBS symptoms.

Enrollment: 100 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients newly diagnosed with IBS and H.pylori

Exclusion criteria

• Patients received previous treatment of H.pylori
• Patients receiving treatment for IBS.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Patient with IBS

Experimental group

Description:

Patients with IBS and positive H. pylori.

Treatment:

Drug: Triple therapy for H.pylori